Eli Lilly said on Monday its oral weight-loss drug Foundayo significantly reduced breathing interruptions during sleep in obese adults with moderate-to-severe obstructive sleep apnea, meeting the main goal of a late-stage study.
Foundayo reduced breathing interruptions by up to 44% on average at 52 weeks as measured by a diagnostic scale used to measure the severity of sleep apnea, Lilly said.
Obstructive sleep apnea is a sleep disorder in which the upper airway repeatedly collapses during sleep, lowering oxygen levels and disrupting breathing.
About Foundayo
Foundayo is a prescription medicine used with a reduced-calorie diet and increased physical activity to help some adults with overweight with weight-related medical problems, or adults with obesity, to lose excess body weight and keep the weight off.
Foundayo should not be used with other GLP-1 receptor agonist medicines. It is not known if Foundayo is safe and effective for use in children.
About Sleep Apnea
Sleep apnea is a potentially serious condition that causes breathing to stop and start several times during sleep. People with the condition snore loudly and feel tired even after a full night of sleep.
The main types of sleep apnea are:
Obstructive sleep apnea. Also known as OSA, this more common form of sleep apnea occurs when throat narrowing blocks the flow of air into the lungs.
Central sleep apnea. Also known as CSA, this type of sleep apnea occurs when the brain doesn’t send proper signals to the muscles that manage breathing.
Treatment-emergent central apnea syndrome, also known as complex sleep apnea. This form of sleep apnea happens when OSA — diagnosed with a sleep study — converts to CSA when receiving sleep apnea therapy.
Sleep apnea treatment can ease symptoms and might help prevent complications, such as heart problems.



















